Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats.
Platelets from diabetic patients are hypersensitive to aggregating agents. An imbalance in thromboxane/prostacyclin synthesis has been postulated as an antecedent to the development of diabetic retinopathy. We studied 3-month streptozotocin-diabetic rats (SDR) treated with 200 mg/kg/day p.o. of ditazol, an antiplatelet drug that inhibits thromoboxane formation. Thromboxane B2 (TxB2) production was higher and 6-keto-PGF1 alpha synthesis lower in SDR than nondiabetic rats (NDR). In treated animals, ditazol inhibited platelet aggregation by 66%, and TxB2 production by 58%, and increased vascular 6-keto-PGF 1 alpha by 45%. Furthermore, 13% of the retinal surface was covered by peroxidase-labelled vessels in NDR, 2.1% in nontreated SDR, and 8.9% in SDR treated with ditazol. We postulate that ditazol may prevent or reduce diabetic retinopathy.
Moreno
A
A
Department of Ophthalmology, School of Medicine, University of Málaga, Spain.
De La Cruz
J P
JP
Mérida
F
F
García Campos
J
J
Sánchez de la Cuesta
F
F
D000818:Animals; D001012:Aorta, Abdominal / Q000378:metabolism; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications*; D003930:Diabetic Retinopathy / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D004353:Drug Evaluation, Preclinical; D011464:Epoprostenol / Q000096:biosynthesis*; D008297:Male; D010080:Oxazoles / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012171:Retinal Vessels / Q000187:drug effects*; D013929:Thromboxane B2 / Q000096:biosynthesis*
D010080:Oxazoles; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D011464:Epoprostenol; C084774:ditazol; D001241:Aspirin